International Journal of Hematology

DOI: 10.1007/s12185-012-1121-y Pages: 164-170

Remission induction in acute myeloid leukemia

1. Memorial Sloan Kettering Cancer Center, Leukemia Service

Correspondence to:
Martin S. Tallman
Tel: +1-212-6393842
Fax: +1-212-6393841



Inducing a complete remission (CR) in patients with acute myeloid leukemia is a prerequisite to long-term disease control with subsequent post-remission consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. The use of 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 + 3) has become the standard of care to induce CR, based on clinical trials conducted in the 1980s. Efforts to improve on the CR rate seen with the 7 + 3 regimen that translates into better overall patient survival have been disappointing. Here we review recent phase III studies of novel induction strategies that show promise in increasing the rate of CR and improving disease outcome.

This article is freely available, click here to access the full text/PDF

Share the Knowledge